ACTRN12605000375651已完成1 期
Phase I/II study to find the maximum tolerable dose of the combination of capecitabine and oral cyclophosphamide in the treatment of advanced cancer
Dr Michael Findlay0 个研究点目标入组 40 人开始时间: 2005年9月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 ot stated（—）
- 性别
- All
入选标准
- •Histological / cytological evidence of carcinoma; performance status (WHO) 0-2; adequate bone marrow, renal and hepatic function;recovery from prior chemotherapy toxicity and calculated creatine clearance >50ml/min.
排除标准
- •Lack of physical integrity of upper GI tract; more than 2 prior courses of chemotherapy; prior pelvic radiation; pregnant or lactating; investigational drug within 4 weeks; history of clinically significant cardiac disease or MI in past 12 months.
研究者
相似试验
已完成
1 期
A study to determine the maximum tolerated dose and activity of the combination of romidepsin and carfilzomib in relapsed or refractory peripheral T-cell lymphomaCancerISRCTN42054893niversity of Birmingham (UK)58
进行中（未招募）
1 期
A phase I/II study to find the safe dose of the combination of romidepsin and carfilzomib (phase I) in patients with relapsed or refractory T-Cell lymphoma. The phase II part of the study will look at the activity of the combination.Peripheral T-cell LymphomaMedDRA version: 20.0Level: PTClassification code 10034626Term: Peripheral T-cell lymphoma unspecified refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10034625Term: Peripheral T-cell lymphoma unspecified recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001879-20-GBniversity of Birmingham57
撤回
不适用
A phase I study to determine the maximum tolerable dose (MTD) of weekly carboplatin with the Wee1 inhibitor AZD1775 in patients with p53 mutated solid tumors.NL-OMON45937Antoni van Leeuwenhoek Ziekenhuis30
招募中
不适用
Phase 1 study to determine the maximum tolerated dose and to assess the safety, pharmacokinetics, and efficacy of AVI-3207 Inj. in patients with neovascular age-related macular degeneratioDiseases of the eye and adnexaKCT0004887Avixgen9
已完成
1 期
A Phase I Study of LBH589 in Children With Refractory Solid and Central Nervous System (CNS) TumoursACTRN12609000978268Australian and New Zealand Children's Haematology and Oncology Group (ANZCHOG)52